Depression represents a global mental health concern, and disproportionally affects women
as they are twice more likely to be diagnosed than men. In this review, we provide a …

Key Clinical Points Postpartum Depression Postpartum depression is a common, disabling,
and treatable problem that affects the woman, infant, and family. Sensitive inquiry about …

Background Post-partum depression is associated with substantial morbidity, and improved
pharmacological treatment options are urgently needed. We assessed brexanolone …

Pregnancy is a complex and vulnerable period that presents a number of challenges to
women, including the development of postpartum psychiatric disorders (PPDs). These …

Background Post-partum depression is a serious mood disorder in women that might be
triggered by peripartum fluctuations in reproductive hormones. This phase 2 study …

Ten to twenty percent of postpartum women experience anxiety or depressive disorders,
which can have detrimental effects on the mother, child, and family. Little is known about the …

Objective To understand how giving birth during the coronavirus disease 2019 (COVID‐19)
pandemic affected women based on birth parameters (gestational age, type of birth and …

Background The perinatal period is a time of high risk for onset of depressive disorders and
is associated with substantial morbidity and mortality, including maternal suicide. Perinatal …

BackgroundEvidence on risk factors for postpartum depression (PPD) are fragmented and
inconsistent. AimsTo assess the strength and credibility of evidence on risk factors of PPD …

Background Brexanolone is currently the only treatment specifically approved for postpartum
depression (PPD) in the United States, based on the results from one Phase 2 and two …